Arkolith/Insider Trading/ODTX/Form 4

Glick Gary D

See Remarks, DirectorOdyssey Therapeutics, Inc. (ODTX) · full profile →Form 4 · filed May 11, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
1 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 11, 2026Conversion(C)27K——416K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 11, 2026Conversion(C)100K——0
May 11, 2026Conversion(C)166K——0
May 7, 2026Grant(A)884K—$0884K

Transaction Codes

C
Conversion of a derivative
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-217585) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML